|
|
Article: Endocare Signs Agreement With Qualigen to Integrate 15-Minute PSA Test Into Endocare's New Diagnostic Workstation.
- Article from:
- PR Newswire
- Article date:
- June 4, 2001
CopyrightCOPYRIGHT 2001 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Endocare Advances Total Urology Solutions Strategy With Launch of Diagnostic
Workstation to Provide Patients with Enhanced Testing for Prostate Disease
IRVINE, Calif., June 4 /PRNewswire/ --
Endocare, Inc. (Nasdaq: ENDO), a developer of innovative temperature-based treatments for prostate cancer and prostate obstruction, today announced that it has signed an exclusive OEM agreement with privately held Carlsbad, CA-based Qualigen, Inc. Under the agreement, Endocare will integrate Qualigen's FDA-approved, 15-minute total prostate specific antigen (Total PSA) test into Endocare's newly developed diagnostic workstation for Urology. The ...